HIGHLIGHTS
- who: Mohamad Sabbah and collaborators from the Hematology Department, Pitie-Salpetriere Hospital, Paris, France have published the research: CAR-NK Cells: A Chimeric Hope or a Promising Therapy?, in the Journal: Cancers 2022, 14, 3839. of /2022/
- what: In allogenic HSCT, the main objective is to replace normal hematopoiesis, but also the immune system of the patient, with that from an allogenic donor.
- how: A new study by Prime Therapeutics using real-world data found that the total cost averages more than USD 700000 and can exceed USD 1 million in some cases . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.